Get startedLog in
    Picture of Churchill Capital XI logo

    CCXIU — Churchill Capital XI News Story

    0.000.00%
    us flag iconLast trade - 00:00
    FinancialsSpeculativeMid CapNeutral
    All News

    Brief: ChemoCentryx Reports Results from Ongoing Trial of CCX559 at AACR Annual Meeting 2022

    Picture of Churchill Capital XI logoChurchill Capital XI
    13/04/2022 13:41
    April 13 (Reuters) - ChemoCentryx Inc  CCXI.O :
    * CHEMOCENTRYX REPORTS PHARMACOKINETIC AND PHARMACODYNAMIC
RESULTS
FROM ONGOING PHASE I TRIAL OF ORALLY ADMINISTERED PD-L1
INHIBITOR, CCX559, AT AMERICAN ASSOCIATION FOR CANCER RESEARCH
(AACR) ANNUAL MEETING 2022

Source text for Eikon:  ID:nGNX4NNxwq 
Further company coverage:  CCXI.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Churchill Capital XI

    See all news